Invention Grant
- Patent Title: Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
-
Application No.: US16326977Application Date: 2017-08-23
-
Publication No.: US11236121B2Publication Date: 2022-02-01
- Inventor: Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
- Applicant: Sage Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Sage Therapeutics, Inc.
- Current Assignee: Sage Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Honigman LLP
- Agent Kathryn D. Doyle; Jonathan P. O'Brien
- International Application: PCT/US2017/048267 WO 20170823
- International Announcement: WO2018/039378 WO 20180301
- Main IPC: C07J43/00
- IPC: C07J43/00 ; C07D231/14 ; A61P37/00 ; A61P25/22 ; A61P25/18 ; A61P25/24 ; A61P25/00 ; A61P25/08

Abstract:
This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
Public/Granted literature
- US20190177359A1 A CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID Public/Granted day:2019-06-13
Information query